Harryanto Reksodiputro A, Hilman Tadjoedin, Iman Supandiman, Nuzirwan Acang, Azmi S. Kar, Made Bakta I, Andi Fachruddin Benyamin, Ami Ashariati, Suharti C, Ikhwan Rinaldi, Nadia Salim, Wulyo Rajabto, Nugroho Prayogo, Demak L. Tobing, Meilani Syampurnawati, Johan Kurnianda, Suradi Maryono, Budi Darmawan Machsoes, Mediarty Syahrir, Darwin Prenggono M, Harlinda Haroen Kumaat, Resti Mulya Sari, Sri Agustini, Toman L. Toruan and Delta Fermikuri Akbar
Aim: To assess CML patient’s characteristic including demographic, clinical and hematological characteristic of patients with CML including quantitative BCR-ABL and BCR-ABL gene sequencing.
Methods: This study was an open-label, single arm, non-randomized, cross sectional study in patients with CML being treated with imatinib mesylate (IM) from 12 centers.
Result: A total of 100 patients were evaluated between January 1, 2009 and December 31, 2011. The median age was 34-35 years old (mean of age is 36 years old), and more patients in the productive age was found. ------- (?) were 80 of the 100 patients who had been examined for the BCR-ABL gene mutation with the sequencing method before consuming IM. Mutation in the P-loop was seen in 2,27% (1 out of 44 patients), this finding was beyond our expectation since 47,69% (31 out of 65 patients) of our patients did not achieved CHR at three months. On the other hand, 15,9% (7 out of 44 patients) of our patients had mutation outside the P-loop.
Conclusions: The characteristics of CML patients in Indonesia were not different from CML patients in Asia in general. Our finding concerning the high frequency mutation in the BCR-ABL gene outside the P-loop needs further study.